Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Buruli Ulcer/*diagnosis ; Buruli Ulcer/*pathology ; CD4-Positive T-Lymphocytes/*immunology ; CD40 Ligand/*analysis ; Cytokines/*analysis ; Mycobacterium ulcerans/*immunology ; T-Lymphocyte Subsets/*immunology; Adolescent ; Biomarkers/analysis ; Case-Control Studies ; Cells, Cultured ; Child ; Child, Preschool ; Disease Progression ; Female ; Humans ; Infant ; Male
    • Abstract:
      Background: Buruli ulcer disease (BUD), caused by Mycobacterium (M.) ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. BUD causes necrotic skin lesions and is a significant problem for health care in the affected countries. As for other mycobacterial infections, T cell mediated immune responses are important for protection and recovery during treatment, but detailed studies investigating these immune responses in BUD patients are scarce. In this study, we aimed to characterise M. ulcerans-specific CD4+ T cell responses in BUD patients and to analyse specific cytokine-producing T cells in the context of disease severity and progression.
      Methodology/principal Findings: For this case-control study, whole blood samples of BUD patients (N = 36, 1.5-17 years of age) and healthy contacts (N = 22, 3-15 years of age) were stimulated with antigen prepared from M. ulcerans and CD4+ T cells were analysed for the expression of TNFα, IFNγ and CD40L by flow cytometry. The proportions and profile of cytokine producing CD4+ T cells was compared between the two study groups and correlated with disease progression and severity. Proportions of cytokine double-positive IFNγ+TNFα+, TNFα+CD40L+, IFNγ+CD40L+ (p = 0.014, p = 0.010, p = 0.002, respectively) and triple positive IFNγ+TNFα+CD40L+ (p = 0.010) producing CD4+ T cell subsets were increased in BUD patients. In addition, TNFα+CD40L-IFNγ- CD4+ T cells differed between patients and controls (p = 0.034). TNFα+CD40L-IFNγ- CD4+ T cells were correlated with lesion size (p = 0.010) and proportion were higher in 'slow' healers compared to 'fast healers' (p = 0.030).
      Conclusions: We were able to identify M. ulcerans-specific CD4+ T cell subsets with specific cytokine profiles. In particular a CD4+ T cell subset, producing TNFα but not IFNγ and CD40L, showed association with lesion size and healing progress. Further studies are required to investigate, if the identified CD4+ T cell subset has the potential to be used as biomarker for diagnosis, severity and/or progression of disease.
    • References:
      Lancet Glob Health. 2014 Jul;2(7):e422-30. (PMID: 25103396)
      Clin Infect Dis. 2009 Apr 15;48(8):1055-64. (PMID: 19275499)
      J Hyg (Lond). 1975 Feb;74(1):7-16. (PMID: 1054061)
      Clin Infect Dis. 2005 May 1;40(9):1368-71. (PMID: 15825042)
      Clin Exp Immunol. 2006 Mar;143(3):445-51. (PMID: 16487243)
      Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85. (PMID: 20566765)
      Clin Exp Immunol. 2011 Jan;163(1):33-49. (PMID: 20939860)
      J Clin Microbiol. 2009 Apr;47(4):924-6. (PMID: 19204098)
      PLoS Negl Trop Dis. 2015 Jan 08;9(1):e3457. (PMID: 25569674)
      PLoS Negl Trop Dis. 2010 Dec 14;4(12):e911. (PMID: 21179505)
      Infect Immun. 2011 Jan;79(1):421-30. (PMID: 20974825)
      Clin Infect Dis. 2011 Jan 1;52(1):94-6. (PMID: 21148526)
      Infect Immun. 2000 May;68(5):3002-6. (PMID: 10769003)
      Nat Med. 2011 Mar;17(3):372-6. (PMID: 21336285)
      Antimicrob Agents Chemother. 2014;58(2):1161-6. (PMID: 24323473)
      Trans R Soc Trop Med Hyg. 1976;70(5-6):449-57. (PMID: 841647)
      Lancet Infect Dis. 2004 Dec;4(12):761-76. (PMID: 15567126)
      Emerg Infect Dis. 2003 Jun;9(6):651-656. (PMID: 12780997)
      Eur J Immunol. 2009 Mar;39(3):723-9. (PMID: 19224636)
      J Pathol Bacteriol. 1964 Jul;88:169-74. (PMID: 14194975)
      Trop Med Int Health. 2004 Dec;9(12):1297-304. (PMID: 15598261)
      Clin Vaccine Immunol. 2006 Feb;13(2):253-7. (PMID: 16467334)
      Infect Immun. 2004 Feb;72(2):958-65. (PMID: 14742541)
      Infect Immun. 2006 May;74(5):2917-24. (PMID: 16622230)
      PLoS Negl Trop Dis. 2011 Oct;5(10):e1290. (PMID: 22039555)
      Emerg Infect Dis. 2002 Feb;8(2):167-70. (PMID: 11897068)
      Lancet. 2010 Feb 20;375(9715):664-72. (PMID: 20137805)
      PLoS Negl Trop Dis. 2015 Nov 19;9(11):e0004247. (PMID: 26583925)
      PLoS Negl Trop Dis. 2015 Dec 02;9(12):e0004253. (PMID: 26630648)
      Med J Aust. 2009 Nov 16;191(10):564-6. (PMID: 19912091)
      PLoS One. 2015 Mar 05;10(3):e0119737. (PMID: 25742660)
      PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2786. (PMID: 24722524)
      J Infect Dis. 2009 Dec 1;200(11):1675-84. (PMID: 19863437)
      Lancet. 1999 Sep 18;354(9183):1013-8. (PMID: 10501380)
      BMC Infect Dis. 2013 Sep 05;13:416. (PMID: 24007371)
      Infect Immun. 2001 Mar;69(3):1704-7. (PMID: 11179346)
      J Infect Dis. 2011 Feb 1;203(3):378-82. (PMID: 21186260)
      PLoS Negl Trop Dis. 2016 Apr 20;10(4):e0004594. (PMID: 27097163)
      Eur J Clin Microbiol Infect Dis. 2010 Jun;29(6):643-50. (PMID: 20306324)
      Lancet Infect Dis. 2009 Nov;9(11):699-710. (PMID: 19850228)
      Lancet. 1973 Oct 20;2(7834):873-7. (PMID: 4126917)
      Med Microbiol Immunol. 2003 Nov;192(4):211-6. (PMID: 12684759)
      PLoS One. 2010 Jun 21;5(6):e11237. (PMID: 20574540)
      PLoS Negl Trop Dis. 2011 Aug;5(8):e1252. (PMID: 21829740)
      J Immunol Methods. 2014 Dec 1;414:1-10. (PMID: 25224748)
      Can J Infect Dis Med Microbiol. 2016;2016:5310718. (PMID: 27413382)
      Infect Immun. 2002 Oct;70(10):5562-7. (PMID: 12228283)
      J Leukoc Biol. 2006 Jun;79(6):1150-6. (PMID: 16531561)
      Am J Trop Med Hyg. 2009 Jul;81(1):75-81. (PMID: 19556570)
      Cell Immunol. 2015 Nov-Dec;298(1-2):1-8. (PMID: 26302932)
      Infect Immun. 2004 Jan;72(1):62-5. (PMID: 14688081)
      Clin Exp Immunol. 2007 Dec;150(3):451-9. (PMID: 17900302)
    • Grant Information:
      MR/J01477X/1 United Kingdom MRC_ Medical Research Council
    • Accession Number:
      0 (Biomarkers)
      0 (Cytokines)
      147205-72-9 (CD40 Ligand)
    • Publication Date:
      Date Created: 20170228 Date Completed: 20170623 Latest Revision: 20220129
    • Publication Date:
      20240105
    • Accession Number:
      PMC5344519
    • Accession Number:
      10.1371/journal.pntd.0005415
    • Accession Number:
      28241036